What are the symptoms of cytomegalovirus (CMV) infection and how is it treated?

CMV Infection: Symptoms and Treatment

For immunocompromised patients (transplant recipients, HIV/AIDS), treat clinically significant CMV infection with first-line valganciclovir or ganciclovir, reserving maribavir for resistant/refractory cases; for congenital CMV, symptomatic newborns should receive valganciclovir or ganciclovir to prevent hearing loss and improve neurodevelopmental outcomes.

Clinical Presentation and Symptoms

Immunocompetent Adults

• Most infections are asymptomatic or present with mild influenza-like symptoms, glandular fever-like illness, or hepatitis 1
• Rarely causes serious disease in this population

Congenital CMV Infection

At Birth (Symptomatic - 1 in 8 infected babies):

• Jaundice
• Petechial rash
• Hepatosplenomegaly
• Microcephaly (small brain)
• Small for gestational age
• Thrombocytopenia 1, 2

Asymptomatic at Birth (7 in 8 infected babies):

• No clinically detectable signs initially
• Risk of delayed sequelae: hearing loss and mental retardation developing later 1, 2

Immunocompromised Patients (Transplant Recipients, HIV/AIDS)

Gastrointestinal Disease:

• Erosive or ulcerative lesions anywhere from mouth to rectum
• Symptoms depend on location: abdominal pain, bloody stools, poor weight gain 3

CNS Manifestations:

• Diffuse encephalitis
• Ventriculoencephalitis
• Cerebral mass lesions
• Transverse myelitis
• Polyradiculomyelitis 4

Post-Transplant:

• Rising CMV DNAemia on monitoring
• Organ-specific disease manifestations
• Most common viral infection in first month after CAR T-cell therapy (17-56% incidence) 5

Treatment Approach

First-Line Treatment for Immunocompromised Patients

Standard Therapy:

• Valganciclovir (oral) or ganciclovir (IV) for clinically significant CMV infection 5, 6, 7
• Monitor CMV DNAemia with real-time PCR to guide preemptive therapy 6

Special Considerations:

• Patients with neutropenia: Consider maribavir if valganciclovir cannot be used 5
• Patients with renal impairment: Avoid foscarnet if possible; consider maribavir 5
• CNS or ocular disease: Do NOT use maribavir (poor penetration); use ganciclovir or foscarnet 5

Resistant or Refractory CMV Infection

Second-Line Treatment:

• Maribavir (oral) is now recommended as second-line therapy for resistant/refractory CMV after allogeneic HCT, showing higher response rates and lower organ toxicity than alternatives 5, 6, 7
• Critical caveat: Maribavir has poor CNS and ocular penetration—never use for disease in these sites 5
• Check for pre-existing maribavir resistance mutations before starting 5

Alternative Options:

• Foscarnet (IV)
• High-dose ganciclovir (7.5-10 mg/kg every 12h if tolerated)
• Cidofovir (second choice)
• CMV-specific T-cell therapy (emerging option) 5

Congenital CMV Treatment

Symptomatic Newborns:

• Valganciclovir or ganciclovir reduces hearing loss in 5 out of 6 babies and improves long-term neurodevelopmental outcomes 1
• All infected infants require follow-up minimum 2 years to monitor hearing and brain development 1

Maternal Treatment (Prevention):

• Valaciclovir started after primary CMV infection in first 12 weeks of pregnancy reduces risk of fetal infection 1

Testing Requirements:

• Test all babies born to mothers with confirmed/suspected CMV with urine or saliva sample within first 21 days of life 1

Gastrointestinal CMV Disease

• Ganciclovir or foscarnet often heals intestinal lesions 3
• Requires mucosal biopsy showing CMV by histopathology for diagnosis 3

Prevention Strategies

Transplant Recipients:

• Letermovir prophylaxis recommended for CMV-seropositive adult allo-HSCT recipients with negative CMV DNAemia 6, 7
• Letermovir has decreased incidence of clinically significant CMV infection and resistant/refractory infections 5
• No mandatory universal prophylaxis for solid organ transplant recipients 6

Pregnant Women:

• Hygiene-based measures: handwashing, especially for those in contact with young children (primary source of infection) 1
• Most guidelines recommend against universal screening, though controversy exists 8

Critical Pitfalls to Avoid

1. Never use maribavir for CNS or ocular CMV disease—it does not penetrate these sites adequately 5
2. Do not combine maribavir with valganciclovir/ganciclovir—combination not recommended 5
3. Maribavir has lower threshold for resistance development than other agents 5
4. All congenital CMV infections require long-term follow-up, even if asymptomatic at birth—1 in 9 asymptomatic babies develops sequelae 1, 2
5. Resistance testing should guide therapy changes in refractory cases 5